IP Verse

Amgen Europe competitive analysis

Latest publications and patents of Amgen Europe New

Explore the latest publications and patents granted to Amgen Europe, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Amgen Europe

EP2651400
Jan 18, 2023Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses ThereofPatent Maintained As Amended
EP3320902
Feb 17, 2021Methods For Treating Diseases Using Isoindoline CompoundsRevoked
EP2797581
May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneRevoked
EP2687213
Jul 17, 2019Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses ThereofRevoked
EP2223688
May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofRevoked
EP2962690
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofRevoked

Latest oppositions filed by Amgen Europe

Explore patent oppositions filed by Amgen Europe against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023
EP3145487
Liquid Pharmaceutical CompositionARES TRADINGDec 20, 2018

Latest patents of Amgen Europe opposed by its competitors

Explore Amgen Europe's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2651400
Jan 18, 2023Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof1
EP3320902
Feb 17, 2021Methods For Treating Diseases Using Isoindoline Compounds1
EP2797581
May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione3
EP2687213
Jul 17, 2019Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof1
EP2223688
May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof5
EP2962690
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof15

Latest PTAB cases involving Amgen Europe

Discover the latest PTAB cases involving Amgen Europe, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Amgen Europe with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
AMGEN EUROPE226 - - Defensive
ARES TRADING512 - 1Balanced
FRESENIUS KABI DEUTSCHLAND11818 - - Highly Aggressive
OSSIFI MAB - 5 - - Non-Active